

Kidney Cancer (Renal Cell Carcinoma) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

Renal Cancer Risk: __Poor __Intermediate __Good

Prior Therapy: _____

Metastatic Disease | First Line of Therapy (1st Line)

- High dose intravenous (IV) interleukin-2 (IL2, Proleukin)*
- Nivolumab (Opdivo) and ipilimumab (Yervoy)*
- Pazopanib (Votrient)
- Sunitinib (Sutent)
- Temozolimus (Torisel)†

Metastatic Disease | Second or Subsequent Lines of Therapy (2nd Line+) | Clear Cell Carcinoma

- Nivolumab (Opdivo)

*Indicated only for tumors with a significant clear cell histology component

†Indicated only for poor prognosis and non-clear cell histology. Poor prognosis is based on the Motzer criteria (<https://www.mdcalc.com/memorial-sloan-kettering-cancer-center-mskcc-motzer-score-metastatic-renal-cell-carcinoma-rcc>)

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue
South Tower - Suite 800 Chicago, IL 60631
www.aimspecialtyhealth.com

Last review: 05/22/2018 | Effective date: 08/06/2018

Appropriate.Safe.Affordable

© 2018 AIM Specialty Health
9013-0818b